TEVA vs. TAK, ARGX, BNTX, ONC, SMMT, GMAB, ITCI, VTRS, MRNA, and RDY
Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries vs.
Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Teva Pharmaceutical Industries has a consensus target price of $23.57, indicating a potential upside of 41.53%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries received 1231 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.87% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Takeda Pharmaceutical has a net margin of 4.53% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Takeda Pharmaceutical's return on equity.
9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 5 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Takeda Pharmaceutical's score of 0.26 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.
Summary
Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 12 of the 18 factors compared between the two stocks.
Get Teva Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teva Pharmaceutical Industries Competitors List
Related Companies and Tools
This page (NYSE:TEVA) was last updated on 2/21/2025 by MarketBeat.com Staff
